Simcere Pharmaceutical Group, the Nanjing-based generic pharmaceutical maker, is relying on PR counsel and representation in the U.S. and China as it becomes the latest Chinese company to pull out of a U.S. stock listing.
Brunswick Advises Latest Chinese Firm Going Private
Wed., Aug. 28, 2013
By Greg Hazley
Read Full Story in Subscriber Area
Category: M&A
More M&A posts from O'Dwyer's:
• | Spectrum Acquires ContinuumThu., Feb. 8, 2024 |
• | When it's Time to Sell Your PR AgencyFri., Jan. 19, 2024 |
• | Selling Your PR Agency? Your Employees Might Thank YouFri., Oct. 13, 2023 |
• | Kekst Works Palladium's NAP AcquisitionThu., Jul. 6, 2023 |
• | ICR Acquires Bullfrog + BaumTue., Jun. 6, 2023 |
No comments have been submitted for this story yet.